Novartis International AG: Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19 1 Detailed results will be submitted for publication to support scientific understanding of JAK inhibition in COVID-19 and inform ongoing research Novartis commitment to address COVID-19 pandemic remains strong with multiple research collaboration initiatives ongoing Basel, December 14, 2020 - Novartis today announced that the Phase III RUXCOVID study evaluating ruxolitinib on top of standard of care (SoC) therapy compared to SoC treatment alone in patients with COVID-19 did not meet its primary endpoint 1. Initial data show there was no statistically significant reduction in the proportion of patients on ruxolitinib plus SoC therapy who experienced severe complications, including death, respiratory failure requiring mechanical ventilation or admission to the intensive care unit (ICU) by Day 29, compared to SoC alone